Related Experiment Video
Updated: Jul 4, 2026
08:41
Adeno-associated Virus-mediated Transgene Expression in Genetically Defined Neurons of the Spinal Cord
Published on: May 12, 2018
Sustained analgesic peptide secretion and cell labeling using a novel genetic modification
Shyam Gajavelli1, Daniel A Castellanos, Orion Furmanski
1The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, FL 33136, USA. SGajavel@med.miami.edu
Cell Transplantation
|June 5, 2008
Summary
Engineered cells can secrete analgesic peptides and retain an intracellular label for tracking, offering a novel approach for neuropathic pain therapy. This method enables dual protein targeting from a single genetic construct.
Area of Science:
- Biotechnology
- Neuroscience
- Pharmacology
Background:
- Cell-based therapies offer sustained delivery of analgesics for neuropathic pain.
- Engineering cells to produce analgesic peptides and track them is crucial for efficacy.
- Conventional genetic constructs target proteins to either extracellular or intracellular compartments.
Purpose of the Study:
- To develop a single genetic construct for simultaneous secretion of an analgesic peptide and intracellular retention of a fluorescent label.
- To investigate the delivery of proteins with distinct subcellular destinations from one construct.
- To assess the therapeutic potential of engineered cells in a neuropathic pain model.
Main Methods:
- A synthetic gene for [Ser1]-histogranin (SHG) was combined with a secretion signal (NGF-beta) and an intracellular label (mRFP) with a cleavage site.
- A lentiviral vector was used for gene delivery, incorporating an endoplasmic reticulum retention signal (KDEL) for mRFP.
- Cells were analyzed using immunocytochemistry, confocal microscopy, dot blot, and Western analysis; transplanted cells were tested in a rodent pain model.
Main Results:
- A single SHG-mRFP polypeptide was synthesized and correctly processed/targeted in transduced cells.
- Stable transduction and long-term secretion of SHG from PC12 cells were confirmed in vitro.
- Transplanted cells demonstrated modest analgesia in a rodent pain model, correlating with detectable SHG levels in cerebrospinal fluid.
Conclusions:
- It is feasible to co-deliver proteins with different destinations (secreted peptide and intracellular label) from a single genetic construct.
- This dual-targeting strategy holds promise for cell-based therapies requiring both therapeutic agent secretion and cell tracking.
- The approach provides a foundation for developing advanced cell therapies for neuropathic pain and other conditions.
